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ABSTRACT
Protein kinases play a central role in the oncogenesis of colorectal tumors 
and are attractive druggable targets. Detection of activated kinases within a tumor 
could open avenues for drug selection and optimization of new kinase inhibitors. By 
using a phosphokinase arrays with human colorectal tumors we identified activated 
kinases, including the Epidermal Growth Factor Receptor (EGFR), components of the 
PI3K/mTOR pathway (AKT and S6), and STAT, among others. A pharmacological 
screening with kinase inhibitors against these proteins helped us to identify a new 
kinase inhibitor, termed EC-70124 that showed the highest anti-proliferative activity 
in cell lines. EC-70124 also inhibited cell migration and biochemical experiments 
demonstrated its effect targeting the PI3K/mTOR pathway. This drug also arrested 
cells at G2/M and induced apoptosis. Experiments in combination with standard 
chemotherapy used in the clinical setting indicated a synergistic effect. EC-70124 
also reduced tumor growth in vivo and inhibited pS6 in the implanted tumors. In 
conclusion, by studying the kinase profile of colorectal tumors, we identified relevant 
activated pathways, and a new multi-kinase compound with significant antitumor 
properties.
INTRODUCTION
Different molecular alterations have been described 
in colorectal cancer. Among them, the unbalanced 
activation of protein kinases plays a central role [1]. Several 
of these proteins, including receptor tyrosine kinases 
(RTK) or signaling downstream mediators, have been 
associated with the initiation, maintenance and progression 
of this tumor type [1]. An example is the expression of 
the Epidermal Growth Factor Receptor (EGFR), and the 
Vascular Endothelial Growth Factor Receptor (VEGFR) 
in colorectal cancer, that led to the clinical development 
of drugs against them, such as panitumumab or cetuximab 
against EGFR, and bevacizumab against VEGFR 
[1, 2]. This activation is also associated with an oncogenic 
advantage, as pharmacological inhibition with the 
mentioned compounds is linked with clinical benefit [3, 4].
Taken into account that solid tumors, and 
particularly colorectal cancer, is a heterogeneous disease 
[2], the understanding of the kinase profile of this 
tumor could help in the selection of relevant therapeutic 
strategies. This approach has been used previously to 
identify the PI3K/mTOR route as a relevant target in a 
subtype of breast tumors [5]. In addition, the increase 
therapeutic efficacy observed when acting concomitantly 
against several kinases compared with single kinase 
inhibition, suggests that the identification, selection, and 
therapeutic optimization of inhibitors with a broader 
effect on relevant proteins kinases can represent a better 
therapeutic strategy, if there is no increase in toxicity [6].
In this regard, several proteins and signaling routes 
are clearly activated in colon cancer and linked with 
tumorigenesis. Some of them include the PI3K/mTOR 
pathway, the Mitogen Activated Protein Kinase (MAPK) 
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route, angiogenesis pathways or routes associated with 
migration such as the FAK family of kinases [7, 8]. In 
parallel with this, some of these routes have been linked 
with resistance to targeted therapies against known 
oncogenes reinforcing the concept that a global kinase 
picture could undoubtedly provide useful information [9]. 
Therefore, a desirable approach would be the development 
of polypharmacology inhibitors targeting simultaneously 
several of these relevant pathways and proteins.
In the present work, we planned to explore the 
kinase profile of primary colorectal tumors; and based 
on these findings, to perform a pharmacologic screening 
to recognize kinase inhibitors with anti-proliferative 
effect. We identified a novel compound termed EC-70124 
with an ample inhibitory spectrum including the PI3K/
mTOR pathway and SRC. EC-70124 showed inhibition 
of proliferation and migration in preclinical models; 
and tumor growth inhibitory properties in animals. 
Furthermore, this compound induced DNA damage 
and synergized with chemotherapy used in the clinical 
setting. Taken together this data support the future clinical 
evaluation of this compound in colorectal tumors.
RESULTS
Phospho-kinase profile of human colorectal 
tumors
We analyzed the activation status of several 
RTKs and relevant signaling mediators in samples from 
eighteen patients diagnosed with colorectal cancer. To do 
so, we used two antibody-based array kits that evaluate 
the phosphorylation status of these proteins, as shown 
in Supplementary Figure S1. Patient characteristics are 
described in Table 1.
The analyses revealed that of the fifty-nine proteins 
evaluated, only twenty-three were phosphorylated 
(Figure 1A). The most phosphorylated RTKs involved 
members of the ErbB receptor family (EGFR: 88.8%, n = 
16; ErbB2: 50%, n = 9; ErbB3: 38.8%, n = 7; ErbB4 27.7%, 
n = 5); followed by Alk (77.7%, n = 14), FGFR1 (61%, n = 
11), FGFR3 (55.5%, n = 10), AXL (61%, n = 11), PDGFR 
beta (55.5%, n = 10) or IR (50%, n = 9), among others. 
We also observed activation of VEGFR1 (44%, n = 8) and 
VEGFR3 (44%, n = 8). Phosphorylation of downstream 
signalling regulators included components of the PI3K/
mTOR/AKT pathway (AKT/Thr 308: 83%, n = 15; pS6: 
83%, n = 15) and STAT1 (83%, n = 15) (Figure 1A). 
Next, we correlated the expression of RTKs and down-
stream mediators observed in human samples with those 
of two representative cell lines of colorectal cancer, 
SW620 and HT29. As can be seen in Figure 1B, some 
of the most activated RTKs and downstream mediators in 
human samples were also activated in SW620 or HT29, 
confirming that these cell lines can be considered as a 
good representative model.
Given the fact that selection of anti-EGFR therapies is 
based on the presence of K-RAS mutations and that tumors 
with constitutive activation of downstream mediators can 
present secondary activating loops, we interrogated if 
differences in the kinase profile among the two groups could 
be identified. Therefore, we compared the kinase profile 
in K-RAS mutated (n = 8) versus non-mutated (n = 10) 
tumors. Expression of EGFR was similar in both groups, 
but ALK, AKT/Thr308 and STAT1 were reduced in tumors 
with K-RAS mutations (Figure 1C). No differences were 
observed for the expression of pErk1/2. Other kinases 
whose phosphorylation was reduced in K-RAS mutated 
tumors included MSPR, FGFR3 and ErbB3 (Figure 1C).
Finally, we observed that an important number 
of proteins were phosphorylated within the same tumor 
(Figure 1D), supporting the idea that targeting of several 
proteins or key signalling nodes could be a rational approach.
Pharmacologic evaluation with multi-kinase 
inhibitors
Next, we decided to evaluate the effect on cell 
proliferation of several kinase inhibitors designed against the 
most frequently phosphorylated kinases observed in human 
samples. We evaluated six different agents, including some 
agents approved in cancer for other indications and a multi-
kinase inhibitor currently in preclinical development. The 
agents included lapatinib, as an EGFR and ErbB2 inhibitor, 
sunitinib as a VEGFR2 and PDGFRβ inhibitor, crizotinib as 
a c-MET and ALK inhibitor, dasatinib as a Abl, SRC and 
c-Kit inhibitor, BEZ235 as a dual pan-PI3K/mTOR inhibitor, 
and NVP-BSK805 as a JAK/STAT inhibitor (Figure 2A). 
In addition, we evaluated a novel polypharmacology kinase 
inhibitor termed EC-70124, a hybrid indolocarbazole 
obtained by combinatorial biosynthesis of Rebeccamycin and 
Staurosporin genes [10].
The effect on cell proliferation of these compounds 
was evaluated in two colon cancer cell lines SW620, and 
HT29 using the MTT metabolization assay. By doing a 
dose response curve we observed different sensitivity to the 
drugs evaluated. The proliferation assays showed that the 
new multi-kinase inhibitor EC-70124 had a strong effect in 
the cell lines studied compared with other agents. EC-70124 
reached a half-maximal inhibitory effect in the nanomolar 
range (below 200 nM) in the two cell lines (Figure 2A, 2B). 
At doses below 500 nM only BEZ235 showed a relevant 
effect on growth inhibition in SW620, but limited in HT29. 
Dasatinib showed only antiproliferative effect in HT29.
We also investigated the effect of EC-70124 in three-
dimensional growth using the same cell lines. For this 
purpose, we grew cells in matrigel, a semisolid media where 
the cells grow forming spherical structures. Treatment with 
EC-70124 strongly decreased the diameter of these spheres 
(control vs treatment, mean diameter and SD = 3.62 +/− 
0.11 vs 2.28 +/− 0.08 and 10,63 +/− 0.7 vs 1.1 +/− 0.1 for 
SW620 and HT-29, respectively) (Figure 2C).
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Finally, we evaluated the effect of the drug on cell 
migration. EC-70124 reduced the migration of the two cell 
lines at 24 hours (Figure 2D).
Effect of EC-70124 on the kinase profile of colon 
cancer cell lines
To further evaluate the effect of EC-70124 on the 
kinase profile, we analyzed the phosphorylation status 
of several kinases in SW620 and HT29 before and after 
treatment with the drug at 6, 12 and 24 hours. A common 
pattern for these cell lines was the phosphorylated 
presence of key signalling nodes including the PI3K/
mTOR pathway (AKT and S6) and SRC (Figure 3A, 3B), 
and as described in Figure 1B. In SW620, SRC and LCK 
were strongly activated in basal conditions and treatment 
with EC-70124 caused a strong and maintained inhibition. 
pS6 showed a relevant basal phosphorylation in SW620 
and HT29 that was inhibited at short times. In HT29, pS6 
and SRC which showed the highest phosphorylated level 
among all kinases, were also inhibited. In this cell line 
an increasing activation of Erk1/2 pathway was observed 
after 6 hours of treatment (Figure 3A and 3B).
EC-70124 produces G2/M arrest and induction 
of apoptosis
Next we explored the effect of EC-70124 on cell 
cycle and apoptosis. Propidium iodide staining revealed 
that EC-70124 induced accumulation of cells in the 
G2/M phase (Figure 4A). Using Annexin V staining we 
evaluated the induction of apoptosis. As can be seen in 
figure 4B, treatment with EC-70124 induced apoptosis 
only in SW620, that was confirmed by the biochemical 
evaluation of PARP cleavage (Figure 4D). No such effect 
was observed in HT29 (Figure 4B and 4D). To explore 
the mechanism of cell death we treated both cells with the 
pancaspase inhibitor Z-VAD-FMK and evaluated Annexin 
V staining at 48 hours. No modifications in apoptosis 
was found with the presence of the pancaspase inhibitor 
in HT29, and a small induction in SW620 (Figure 4C). 
This data shows that in SW620 induction of apoptosis was 
both, dependent and independent of caspases.
In a previous evaluation of EC-70124 in breast cancer, 
we observed that EC-70124 led to DNA damage [11]. 
To explore if this effect was also observed in colon cancer, 
we assessed the accumulation of pH2AX and p-chk2 at 
different time points in SW620 and HT29. Treatment 
with EC-70124 augmented the levels of these proteins at 
different time points suggesting that the drug caused DNA 
damage in colon cancer cells (Figure 4D).
EC-70124 synergizes with standard of care 
chemotherapy
As success in cancer therapy is based on drug 
combinations, we investigated the effect of EC-70124 
in association with chemotherapies used in the clinical 
setting for the treatment of metastatic colorectal cancer 
including irinotecan, 5-fluorouracil and oxaliplatin. 
Table 1: Patient and tumor characteristics
Patient age (n = 18) Median 73,5 (range 54–84)
Tumor type (n = 18) Adenocarcinoma 14 (78%)
Patients n = 16 Positive 7 (43,75%)
Negative 9 (56,25%)









M (n = 18) 0 13 (72%)
1 5 (28%)
Kras Mutated (n = 18) Positive 8 (44,4%)
Negative 10 (55,6%)
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Figure 1: Expression of activated forms of RTKs and signaling mediators in human samples of colon cancer. A. The 
histogram shows the percentage of human tumors that exhibited phosphorylated kinases. B. phosphorylated kinases in colon cancer 
cell lines, SW620 and HT29, and its comparison with phosphorylated proteins in human tumors. C. Relative comparison of kinases 
phosphorylation between tumors bearing wild-type and mutated KRAS. D. Expression of activated kinases in each analyzed tumor.
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To identify synergistic interactions we used the Chou-
Talalay algorithm [12] for combination index analysis 
in SW620 and HT29, at different concentrations 
(Figure 5A). Combinations with irinotecan, oxaliplatin 
and 5-fluorouracil were synergistic in the two cell lines, 
at almost all evaluated doses (Figure 5A). Studies with 
clonogenic assays confirmed the increased activity of 
the combinations compared with each agent given alone 
(Supplementary Figure S2A).
Finally, we explored the biochemical mechanism 
of action associated with the combination of EC-70124 
and chemotherapies. We observed how EC-70124 induced 
apoptosis when combined with chemotherapy mainly in 
SW620 (Supplementary Figure S2B).
Effect of EC-70124 on tumor growth in vivo
Finally, to evaluate the effect of EC-70124 in vivo, 
we implanted HT29 in mice and treated animals with 
EC-70124 at a dose of 18 mg/kg i.v. every three days. 
Figure 5B shows the anti-tumor effect of EC-70124 
compared to control. The mean tumor volume (mm3) 
measured every three days was significantly higher in the 
control versus the treated group (day 21 after treatment; 
control vs treated, mean volume 749.43 vs 248.44 mm3, 
SD +/− 401.4 and +/− 248.44, respectively; p = 0.029). 
No differences in body weight were observed among 
treated and control groups (Figure 5C). In parallel we 
studied the pharmacodynamic effect of EC-70124 on 
Figure 2: Pharmacologic screening and effect of EC-70124 on proliferation and migration. A. List of drugs assayed in the study, 
including EC-70124, a novel multikinase inhibitor. Table shows the target proteins and IC50 values in SW620 and HT-29 colon cancer cell lines. 
B. Effect of the different kinase inhibitors on the MTT metabolization of SW620 and HT-29 cell lines. Cells were plated in 48-multiwell plates 
and treated with the indicated concentration of the drugs for 72 h. C. Action of EC-70124 on the morphology of SW620 and HT-29 grown in 
three-dimensional (3D) cultures. Cells were plated in 48 multiwell plates and grown in medium containing matrigel for 7 days in the presence 
of EC-70124 (500 nM). All images were taken at ×20 magnification. The quantification of sphere diameter was performed manually by tracing 
a straight line across the sphere diameter of untreated cells (controls) and scoring its value as arbitrary length units. Data are represented as the 
mean ± s.d of triplicate experiments. Student’s test was used to calculate statistical significance: *P < 0.05 and **P < 0.005. D. Effect of EC-
70124 on wound-healing process in colon cancer cells. SW620 and HT-29 were treated with EC-70124 at 300 nM and photographs were taken 
at 24 hours. Treatments with Dasatinib at 100 nM were used as a negative control of migration. Scale bar represents 500 μm.
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Figure 3: Effect of EC-70124 on RTKs and downstream signaling mediators. A. SW620 and HT-29 cells treated with either 
EC-70124 (500 nM) or drug vehicle for 6 h, 12 h and 24 h were processed for protein extraction. Cell lysates containing 150 μg of total 
protein were analyzed for the expression of phosphorylated proteins by using an antibody array kit. B. Colon cancer cell lines were cultured 
in the presence of EC-70124 (500 nM) for the indicated times and cell lysates were analyzed by western-blot for the levels of different 
proteins as well as their phosphorylated forms.
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Figure 4: Effect of EC-70124 on cell cycle and induction of apoptosis. A. Effect of EC-70124 on the cell cycle of SW620 and 
HT-29. Cells were cultured in DMEM or RPMI + 10% FBS + 5 mM glutamine and treated with 300 nM and 500 nM of EC-70124. Cell 
cycle progression was examined after 24 hours of treatment by flow cytometry using propidium iodide DNA staining. The histogram shows 
the percentage of cells in different phases of the cell cycle. B, C. Apoptotic effect of EC-70124. B) The histogram represents the percentage 
of cells positive and negative for Annexin V staining. C) Cells were treated with EC-70124 in the presence or absence of the pancaspase 
inhibitor Z-VAD-FMK for 48 h, and then stained with Annexin V-DY-634 and propidium iodide. Stained cells were analyzed by flow 
cytometry. D. The levels of p-H2AX, p-CHK2 and cleaved PARP of colon cell lines treated with EC-70124 at different time point were 
determined by Western-blot. GAPDH was used as a loading control.
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Figure 5: Combinational studies in vitro and in vivo antitumor action of EC-70124. A. SW620 and HT-29 cells were treated 
at the indicated concentrations of EC-70124, Irinotecan, Oxaliplatin and 5-Fluorouracil, alone and in combination, and their MTTs values 
were calculated. Combination indexes for the different drug combinations were obtained using CalcuSyn program and plotted. B. Nude 
mice were injected with HT-29 colon cancer cells. When tumors reached 100 mm3 animals were treated intravenously with either drug 
vehicle (control) or EC-70124 (18 mg/kg) for 3–4 days. Data represent the mean +/− s.d. *P < 0.05. C. Body weights curves of untreated 
and treated animals. D. Effect of EC-70124 on expression of p-S6 in mice tumors. Animals were treated for 30 and 60 minutes with EC-
70124 (18 mg/kg iv) and activation of the indicated proteins were analyzed by Western-blotting. GAPDH was used as a loading control. E. 
EC-70124 accumulation in xenografted tumor at 30 min and 60 min: 4 nu/nu mice implanted with HT-29 were treated intravenously with 
18 mg/Kg EC-70124 and two tumors per time point were processed for LC-MS analysis.
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implanted tumors at different time points. As can be 
seen in Figure 5D treatment with the drug reduced pS6 
at different time points (30 and 60 min), confirming the 
effect of this drug on this pathway. Finally, as can be 
seen in Figure 5E, there was a clear accumulation of 
the drug in the tumor at 30 min and 60 min, reaching 
over 3000 ng/g, well above levels with anti-proliferative 
activity in cell lines.
DISCUSSION
Protein kinases are implicated in different cellular 
functions linked with oncogenic transformation [13]. 
In solid tumors several of them are deregulated and 
potentially druggable with kinase inhibitors [13, 14]. In 
the present work we aimed to explore the kinase profile of 
colon cancer using human samples. We observed several 
activated proteins including the ErbB receptor family and 
particularly EGFR, components of the PI3K/mTOR route 
including AKT and pS6, and the JAK/STAT pathway 
represented by STAT1, among others.
EGFR is a well known activated kinase in many 
epithelial tumors including colorectal cancer [15]. Indeed, 
strategies to inhibit this receptor with antibodies or 
small tyrosine kinase inhibitors have reached the clinical 
setting [15]. Examples are cetuximab or panitumumab 
approved for several indications including colorectal or 
head and neck tumors, or EGFR-directed small kinase 
inhibitors in lung cancer [3, 15, 16]. As EGFR activates 
downstream pathways such as the PI3K/AKT/mTOR or 
the MAPK route, we also explored key intermediates of 
these nodes. In addition, activation of the PI3K/mTOR 
pathway is associated with cancer and strategies aimed to 
neutralize their activation are in clinical development in 
different solid tumors [17, 18]. In our study we observed 
the phosphorylation of S6 and AKT/Thr308 in a high 
proportion of patients, showing the relevance of this route 
in colorectal tumors.
Ongoing studies are evaluating agents against the 
PI3K/mTOR route in combination with anti-EGFR antibodies 
in colon cancer [19]. Interestingly, phosphorylation of 
intermediates like AKT and S6 were less prominent in those 
tumors with K-RAS mutations suggesting that strategies 
against the PI3K/mTOR pathway should focus on K-RAS 
wild type tumors. Indeed, our study confirm this strategy, that 
has been incorporated in some clinical studies [19].
An interesting finding was the significant expression 
of phosphorylated ALK and STAT1 in the analyzed human 
samples. In colon cancer, rearrangements of ALK have 
been previously described in a small proportion of tumors 
[20] and the JAK/STAT pathway has been associated 
with the initiation and maintenance of cells with stem cell 
properties [21].
Of note, concomitant activation of several kinases 
were observed within the same tumor. This is a remarkable 
observation as suggests that drugs with activity against 
several relevant routes could have more antitumor activity 
than drugs targeting single proteins.
Next we evaluated different compounds against 
the most frequent phosphorylated kinases. We observed 
how the novel multi-target kinase inhibitor EC-70124 
showed a higher antitumor activity, compared with other 
inhibitors. Biochemical evaluation of the mechanism 
of action of EC-70124 showed that this drug inhi-
bited relevant routes including the PI3K/AKT/mTOR 
pathway. Furthermore, EC-70124 inhibited SRC and 
reduced migration of cancer cells. EC-70124 exerted its 
antineoplastic action through an arrest in G2/M and an 
induction of apoptosis, as indicated by accumulation of 
PARP cleavage in SW620 [22].
Additional experiments demonstrated that EC-
70124 led to DNA damage. This was confirmed by 
phosphorylation of γH2AX and chk2. γH2AX is 
phosphorylated at sites of DNA damage and it is required 
for the recruitment of multiple DNA repair proteins [23]. 
Similarly, after DNA damage chk2 is phosphorylated by 
ATM/ATR kinases.
Most current therapeutic strategies in oncology 
are based on drug combinations, therefore identification 
of synergistic interactions between targeted agents and 
chemotherapies is a main goal [24]. Therefore we decided 
to evaluate EC-70124 in association with relevant drugs 
used in the clinic including oxaliplatin, 5-fluorouracil and 
irinotecan. EC-70124 in combination with these drugs 
showed a synergistic interaction in the cell lines studied. 
We observed how the administration of these combinations 
induced apoptosis particularly in SW620.
Finally, we observed that EC-70124 inhibited tumor 
growth in xenografted mice demonstrating its efficacy in vivo. 
Of note, a reduction of pS6 was also observed confirming the 
effect of the drug on the PI3K/AKT/mTOR route.
In conclusion, in this study we describe the kinase 
profile of human colorectal tumors, reporting some 
druggable kinases and identifying a novel compound 
against some of the activated proteins with clear 
antineoplastic effect. EC-70124 induces cell cycle arrest 
at G2/M and apoptosis. We identify combinations with 
chemotherapies that have a synergistic effect and confirm 
the activity in vivo. Globally, our data support the future 
clinical development of this drug in this clinical setting.
MATERIALS AND METHODS
Patient samples
Colon cancer samples were obtained from the 
tumor bank of the Albacete University Hospital following 
institutional guidelines. All patients signed the study consent 
form. Frozen tissues were collected from 18 randomly 
selected patients who had undergone surgical resection of 
their colorectal tumor. Before processing the samples, cancer 
and benign areas were separated under microscopy analysis.
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Cell lines and drug compounds
SW-620 cell line was obtained from the American 
Type Culture Collection (ATCC; CCL-227) (Manassas, VA) 
and HT-29 cell line was kindly provided by Dr. R. Sánchez-
Prieto. These cells display several genetic alterations; SW-
620 carries mutation in Kras gene, whereas HT-29 has a 
coexisting activating mutation in PIK3CA and BRAF. Cell 
lines were maintained in RPMI (SW620) and DMEM (HT-
29) containing 10% fetal bovine serum (FBS), with 100 U/mL 
penicillin, 100 μg/mL streptomycin and 5 mM L-glutamine. 
The cell culture medium and supplements were obtained 
from Sigma Aldrich (St. Louis, MO). The multi-kinase 
inhibitor EC-70124 was prepared via a proprietary process 
with Entrechem S.L. (Oviedo, Spain). Chemotherapeutic 
agents (Irinotecan, Oxaliplatin and 5-Fluorouracil) were 
purchased from Selleckchem (Deltaclon, Madrid Spain).
Preparation of tumor homogenates and 
phospho-kinase antibody arrays
The tumor samples of patients were minced, 
washed with phosphate-buffered saline buffer (PBS), and 
homogenized in ice-cold RIPA lysis buffer containing 10X 
protease and phosphate inhibitor cocktails (1.5 ml/100 mg of 
tumour). These homogenates were centrifuged at 10000 g for 
10 min at 4°C, and the supernatants were transferred to new 
tubes. For preparation of EC-70124 treated and non-treated 
cell extracts, cell cultures were washed with cold PBS and 
lysed in ice-cold RIPA lysis buffer containing 1X protease and 
phosphate inhibitor cocktails. Then, insoluble material was 
removed by centrifugation. The protein concentration of tumor 
homogenates and cell lines extracts was determined using 
BCA (Bicinchoninic acid) protein assay kit (Sigma Aldrich).
The phosphorylation status of a wide range of 
Receptor Tyrosine Kinase (RTK) and downstream 
signaling nodes was evaluated in both colon cancer 
tissues and EC-70124-treated and non-treated cell lines. 
For these studies, two commercial arrays were used; 
the human phospho-RTK array kit (# ARY001, R&D 
Systems, Abingdon, UK) and the PathScan RTK Signaling 
Antibody Array Kit (# 7982,Cell Signaling Technology). 
According to the manufacturer’s instructions, antibody 
array membranes were incubated with 1,5 mg and 
150 μg of protein lysates, respectively. Quantification 
of the different RTKs and cell signaling intermediates in 
the membranes was performed using the Quantity One 
analysis software (Bio-Rad, CA, USA) and expressed 
as the pixel density (OD/mm2). The pixel density of the 
background was subtracted from the pixel density of each 
spot, and the average of duplicate spots was determined. 
Next, normalized signal intensity was calculated by 
dividing the mean value of pixel density in each spot by 
the mean value of pixel density in the positive control. 
Significance was determined using a cut-off point of 
density signal higher than 0.6.
MTT metabolization, three-dimensional cell 
cultures and clonogenic assays
Cell proliferation experiments were carried 
out using 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny-
ltetrazolium bromide (MTT) assays, where MTT is 
reduced to purple formazan by the mitochondria of living 
cells. Increase in cell number is detected by augmented 
MTT metabolization, and decrease in cell number is 
reflected by decrease in MTT metabolization. SW620 
and HT29 cells were plated at a density of 10,000 cells 
per well in 48-multiwell plates and cultured overnight 
in RPMI or DMEM supplemented with 10% FBS and 
5 mM glutamine The next day, cells were treated for 
three days with increasing concentrations of EC-70124 
alone or in combination with various chemotherapeutics 
to plot the dose–response curves and for synergy 
studies, respectively. In parallel, cells were treated with 
increasing amounts of EC-70124 at three-time points 
(24 h, 48 h and 72 h of incubation) to determine the 
IC50 value. After drug administration, the medium was 
replaced with 400 μL of fresh medium DMEM without 
phenol red containing MTT (0.5 μg/μL) and incubated 
for 45 minutes at 37°C. The medium was then removed 
and 200 μL of dimethylsulfoxide (DMSO) were added 
to each well. The plate was agitated in the dark for 
5 minutes to dissolve the MTT-formazan crystals. The 
absorbance of the samples was recorded at 562 nm (555–
690) in a multiwell plate reader (BMG labtech). Results 
were plotted as the mean values of quadruplicates from a 
representative experiment that was repeated at least two 
independent times.
To determine whether EC-70124 combined to 
other chemotherapy drugs (Irinotecan, Oxaliplatin or 
5-Fluorouracil) was synergistic, additive, or antagonist, 
we used the CalcuSyn v2.0 software programme (Biosoft, 
Ferguson, MO). This program allows the calculation of 
the combination index based on the algorithm of Chou 
and Talalay [12]. Combination index values greater than 
1 indicate antagonism, less than 1 indicate synergism and 
values equal to 1 indicate an additive effect. Combination 
index values from three independent experiments were 
generated.
For Matrigel-embedded cell culture experiments, 
SW620 and HT-29 cells were grown in RPMI or DMEM 
supplemented with 10% FBS and 2 mM glutamine. 
Following passage, cells were trypsinized (0.5 g porcine 
trypsin and 0.2 g EDTA 4 Na, purchased from Sigma 
Aldrich) and resuspended in growth medium containing 
2% Matrigel. Then, cells were seeded at a density of 
12,500 cells/ml in a 48-multiwell plate containing an 
underlying approximately 1 mm thick bed of Matrigel 
and incubated at 37°C. Next day, cells were treated with 
EC-70124 and cultured for 7 days. The assay included the 
daily visualization of cells under a light microscope to 
monitor the phenotype.
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For clonogenic experiments cell were seeded at a 
density of 500,000 cells in a 100 mm culture dishes, and 
treated, the next day, with EC-70124 (500 nM), Irinotecan, 
Oxaliplatin, 5-Fluorouracil, EC-70124 + Irinotecan, EC-
70124 + Oxaliplatin and EC-70124 + 5-Fluorouracil. After 
24-hours treatment, cells were trypsinized, resuspended 
in 5 ml of complete growth medium to perform serial 
dilutions 1/10 and seeded, in triplicate, in 6-multiwell 
plates for 10 days. Then, the medium was removed and 
the number of colonies were determined.
Cell migration study
SW620 and HT-29 cells were plated at a density 
of 200.000 cells/60 mm dish and maintained overnight 
in RPMI + 10% FBS + 2 mM glutamine. Following 
incubation, culture medium was removed and a wound in 
the cell monolayers was generated by scratching with a 
200-μl pipette tip. Photographs were taken of the initial 
wound for comparison. Then, DMEM + 10% FBS was 
added and cells were treated for 48 hours with either 300 nM 
EC-70124 or 100 nM Dasatinib, as a negative control. 
Cell migration was visualized at x10 magnification and 
photographed. Each experiment was completed in duplicate.
Western blotting
For Western-blotting, 50 μg of total protein from 
cell lysates was boiled and resolved by 6%–15% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), depending on the molecular weight of the proteins 
to be analyzed. After electrophoresis, proteins in gels 
were transferred to polyvinylidene difluoride membranes 
(Millipore Corporation). Blots were blocked in 1x Tris-
buffered saline (TBS,100 mM Tris [pH 7.5], 150 mM 
NaCl, 0.05% Tween 20) and 1% of bovine serum albumin 
for 1 hour and then incubated overnight with the following 
primary human monoclonal/policlonal antibodies: anti-AKT, 
anti-pS473-AKT, anti-pH2AX, anti-pCHK2 (BD Biosciences), 
anti-ERK1/2, anti-pERK1/2, anti-PARP-1 (Santa Cruz 
Biotechnology), anti-pS6, anti-pT308-AKT (Cell Signalling 
Technology), anti-Src (Cell Signalling Technology). Protein-
bound primary antibodies were detected using respective 
horseradish peroxidase-coupled secondary antibodies 
(anti-rabbit for polyclonal and anti-mouse for monoclonal, 
obtained from Santa Cruz Biotechnology) diluted 1:5,000 in 
1x TBS containing 0.05% Tween and incubated for 1 hour at 
room temperature. Protein bands were detected using ECL 
Plus Western Blotting Detection System (GE Healthcare, 
Buckinghamshire, United Kingdom).
Cell cycle, and apoptosis detection assays
For cell cycle analyses, SW620 and HT29 cells 
were plated at a density of 500,000 cells/100 mm dish and 
maintained overnight in DMEM + 10% FBS. Cells were 
then treated with 500 nM of EC-70124 for 24 hours. After 
drug treatment, cells were trypsinized, fixed in ice cold 70% 
ethanol for 30 minutes and subsequently centrifuged at 
6000 rpm for 5 minutes. Cell pellets were washed in PBS + 
2% BSA and treated with Propidium iodide/RNAse staining 
solution (Immunostep S.L., Salamanca, Spain) in the dark 
for 1 hour at 4°C, and analyzed then on FACSCanto II 
flow cytometer (BD Biosciences). The percentage of each 
cell cycle phase was determined by plotting DNA content 
against cell number using the FACS Diva software.
For apoptosis analyses, SW620 and HT29 cell 
monolayers were incubated in trypsin–EDTA, washed 
twice with cold PBS, and then resuspended in Annexin V 
binding buffer (Immunostep S.L., Salamanca, Spain) at a 
concentration of 1 × 106 cells per mL. A total of 3 × 105 
cells were incubated for 1 hour in the dark with Annexin 
V (Immunostep) and PI staining solution (5 μL Annexin 
V-DY-634, 3 μL of PI [10 mg/ml final concentration], 
400 μL binding buffer). The apoptotic cells were 
determined using a FACSCanto II flow cytometer (BD 
Biosciences). Both early apoptotic (Annexin V-positive, 
PI-negative) and late (Annexin V-positive and PI-positive) 
apoptotic cells were included in cell death determinations.
In vivo studies
Animal care complied with the Principles of 
Laboratory Animal Care and Guide for the Care and Use 
of Laboratory Animals. HT-29 human colon carcinoma 
cells (5 × 106 cells in 100 μl of DMEM with 20% Matrigel) 
were injected subcutaneously through a 23-gauge needle 
into the back of female BALB/cAnNR1-Fox1 nu/Fox 
1 nu mice (5 weeks old, body weight ~ 18 g) obtained 
from Janvier Labs. Mice were randomly divided into two 
groups: (i) drug treatment group (n = 5) and (ii) control 
group (n = 5). Once tumors reached a volume of 100 mm3, 
animals were inhalatorily anaesthetized and treated with 
either EC-70124 i.v (18 mg/kg) or vehicle i.v. (following 
manufactures instructions) at intervals of 3 to 4 days. Tumor 
diameters were recorded every 3–4 days. The results are 
expressed as tumor volumen, which were calculated using 
the following formula: V = (L × W2)/2, where V = volume 
(cubic millimeters), L = length (millimeters) and W = width 
(millimeters). Mice were killed by CO2 inhalation.
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